What is the growth forecast for the CRPC & HRPCA Therapeutics market?

The market is expected to grow at a CAGR of 8.2% from 2023 to 2028, driven by increasing demand.

What are the key drivers of the CRPC & HRPCA Therapeutics market?

Key drivers include rising prevalence of prostate cancer and growing awareness of treatment options.

What are the challenges facing the CRPC & HRPCA Therapeutics market?

Challenges include high development costs and increasing competition among market players.

Which regions are leading the CRPC & HRPCA Therapeutics market?

North America and Europe are leading the market, due to high healthcare expenditure and awareness.

Who are the top companies in the CRPC & HRPCA Therapeutics market?

Top companies include Johnson & Johnson, Pfizer, and Sanofi, which offer a range of treatment options.

What are the future opportunities in the CRPC & HRPCA Therapeutics market?

Future opportunities include development of novel therapies and increasing adoption of personalized medicine.

How is technology impacting the CRPC & HRPCA Therapeutics market?

Technology is improving diagnosis and treatment, with advancements in genetic testing and targeted therapies.

What is the regulatory landscape like for the CRPC & HRPCA Therapeutics market?

The regulatory landscape is evolving, with increasing focus on patient safety and efficacy of treatments.

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Opportunity by 2034 | In-Depth Report

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics by Application (Hospitals & Clinics, Home Settings, Ambulatory Surgical Centers (ASCs)), by Types (Oral Therapy, Injectable Therapy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.1%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.1%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size | CAGR 8.1 Forecast 2033

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.1%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Overview

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market refers to the industry focused on developing and marketing treatments for prostate cancer that is resistant to castration. As the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size is estimated to be approximately $12.67 billion in 2025, the growth outlook and market forecast indicate a significant expansion of the industry. The industry expansion is driven by increasing demand for effective treatments, with the global market expected to grow at a CAGR of 8.5% during the forecast period from 2026 to 2033. Key forces shaping the industry include advancements in immunotherapy, changes in regulatory frameworks, and shifts in consumer behavior towards more personalized medicine.

Loading chart…

The largest region in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market is North America, driven by high healthcare spending and a large patient population. The fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare infrastructure and awareness about prostate cancer treatments. The market is highly competitive, with key players focusing on developing innovative treatments and combinations to address the complex needs of CRPC patients. Overall, the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market is poised for significant growth, driven by advancements in treatment options and increasing demand for effective therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	23.87 million
Growth rate	CAGR of 8.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astellas Inc.; Johnson & Johnson; Sanofi S.A.; Dendreon Corporation; Bayer AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market is poised for significant growth, driven by increasing demand for effective treatments and a rising patient population. The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in biotechnology and pharmaceutical research have led to the development of innovative therapies, such as immunotherapies and targeted therapies, which are expected to drive growth in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market.

Increasing patient awareness and education regarding the availability of effective treatments for Castration-Resistant Prostate Cancer (CRPC) & HRPCA are contributing to the growing demand for these therapies, subsequently driving market growth.

Restraints2 items

The high cost of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics and limited reimbursement options in some regions may hinder market growth, as patients may be unable to afford these expensive treatments.

Stringent regulatory requirements and clinical trial protocols can delay the approval and launch of new therapies, restraining the growth of the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market.

Opportunities2 items

The growing geriatric population and increasing incidence of Castration-Resistant Prostate Cancer (CRPC) & HRPCA present significant opportunities for market players to develop and commercialize effective treatments, driving growth forecast.

The emergence of personalized medicine and precision therapies is expected to create new opportunities for the development of targeted treatments, further expanding the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size.

Challenges2 items

The complex biology of Castration-Resistant Prostate Cancer (CRPC) & HRPCA and the limited understanding of the underlying mechanisms of resistance pose significant challenges for the development of effective treatments.

The increasing competition in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market and the need for continuous innovation and differentiation can be challenging for market players to maintain their market share and drive growth.

Market Segmentation

Loading chart…

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics segmentation is a crucial aspect of understanding the market dynamics. In terms of Application, the market can be segmented into various categories, including hospital pharmacies, retail pharmacies, and online sales. Each of these segments contributes significantly to the overall market size, with hospital pharmacies being the largest contributor due to the high volume of prescriptions filled.

The Types segment of the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market includes subtypes such as [object Object] and [object Object]. These subtypes are further categorized into specific drug classes, including hormone therapies, chemotherapy, and immunotherapy. The hormone therapies segment holds a significant share of the market due to the high prevalence of CRPC and the effectiveness of these therapies in treating the disease.

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Segmentation Breakdown7 items

Application

Hospitals & Clinics

Home Settings

Ambulatory Surgical Centers (ASCs)

Types

Oral Therapy

Injectable Therapy

Regional Insights

Loading chart…

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of novel therapies and growing infrastructure. Key drivers for North America include investments in research and development, policies supporting healthcare infrastructure, and a mature ecosystem.

In Europe, key drivers include demographics with an aging population, adoption of innovative treatments, and policies promoting access to healthcare. Asia Pacific's growth is driven by investments in healthcare infrastructure, increasing awareness of CRPC and HRPCA, and a growing patient pool. Latin America and Middle East & Africa are expected to experience steady growth, driven by policies supporting healthcare development and increasing access to therapies.

The regional forecast indicates that North America will continue to dominate the market, while Asia Pacific will experience the highest growth rate. Understanding these regional trends is crucial for stakeholders to navigate the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market growth and make informed decisions.

Competitive Landscape

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics competitive landscape is moderately consolidated, with a mix of global players and local companies. The market is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players dominate the market, but local companies are also gaining traction through strategic partnerships and regional expansion. Understanding the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics competitive landscape is crucial for companies to develop effective strategies.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. They focus on technology, service model, channel strength, customization, and cost advantages to gain a competitive edge. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must adapt to these challenges and develop innovative strategies.

Astellas Inc. focuses on regional expansion

Johnson & Johnson prioritizes innovation pipeline

Sanofi S.A. emphasizes premium pricing

Dendreon Corporation invests in local manufacturing

Bayer AG pursues vertical integration

Companies leverage OEM tie-ups

Key Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies5 items

Astellas Inc.

Johnson & Johnson

Sanofi S.A.

Dendreon Corporation

Bayer AG

Market Ecosystem

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics ecosystem encompasses a complex network of stakeholders involved in the development, production, and distribution of therapies for CRPC and HRPCA. This ecosystem spans upstream, midstream, and downstream activities, from technology providers and suppliers to integrators, channels, and end users. Value is created and captured through the interactions and relationships among these stakeholders, ultimately influencing the availability and accessibility of CRPC and HRPCA therapies.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing therapeutic agents

Technology providers — developing novel therapies and formulations

System integrators/EPCs — ensuring regulatory compliance and manufacturing standards

Distributors/channel partners — facilitating therapy delivery to healthcare systems

Regulators/standards bodies — overseeing safety, efficacy, and quality standards

End users/buyers — patients and healthcare providers selecting therapies

In the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics ecosystem, control points are primarily held by regulators and standards bodies, influencing adoption through approvals and quality standards. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and from stringent regulatory requirements. Switching costs, partnerships, and interoperability requirements also impact stakeholders' decisions and the overall ecosystem dynamics. Furthermore, regional differences in healthcare systems, regulatory frameworks, and patient populations can lead to variations in the ecosystem's structure and value chain analysis across different regions.

Recent Industry Insights

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have driven innovation in the field. Notable mergers and acquisitions have also taken place, leading to the expansion of product portfolios and market share. Furthermore, the launch of new products and technologies has improved treatment options for patients, while regulatory changes have paved the way for faster approval of novel therapies.

Additionally, there has been a shift in consumer trends, with an increasing focus on personalized medicine and targeted therapies. Funding rounds and expansions have also been observed, with several companies securing investments to support the development of new treatments. These developments are expected to continue shaping the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics industry trends in the coming years.

Analyst Overview

As the Lead Analyst for this study, I conclude that the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market presents a highly attractive opportunity for pharmaceutical companies. The competitive intensity is moderate, with several key players dominating the market. Looking ahead, the long-term outlook for this market is promising, driven by increasing demand for effective treatments and a growing patient population. The innovation landscape is rapidly evolving, with ongoing research and development focusing on novel therapies and combination treatments. However, the demand–supply balance is a key concern, with some regions experiencing shortages of certain therapies. The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market outlook is positive, but companies must navigate key risk factors, including regulatory challenges and intense competition, to succeed in this space.

11 items

1. Executive Summary

2. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals & Clinics

6.1.2. Home Settings

6.1.3. Ambulatory Surgical Centers (ASCs)

6.2. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Oral Therapy

6.2.2. Injectable Therapy

6.3. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Competition by Key Manufacturers

8.1. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Astellas Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Johnson & Johnson

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sanofi S.A.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Dendreon Corporation

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bayer AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market

Figure 4: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Drivers

Figure 5: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Challenges

Figure 6: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Trends

Figure 7: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Opportunity

Figure 8: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Restraint

Figure 9: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Value (USD Million) By Region

Figure 15: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Value (USD Million) By Region

Figure 23: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Value (USD Million) By Region

Table 10: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Astellas Inc. Basic Information And Sales Area

Table 31: Astellas Inc.. Products Portfolio

Table 32: Johnson & Johnson Basic Information And Sales Area

Table 33: Johnson & Johnson. Products Portfolio

Table 34: Sanofi S.A. Basic Information And Sales Area

Table 35: Sanofi S.A.. Products Portfolio

Table 36: Dendreon Corporation Basic Information And Sales Area

Table 37: Dendreon Corporation. Products Portfolio

Table 38: Bayer AG Basic Information And Sales Area

Table 39: Bayer AG. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Value (USD Million) By Region

Table 45: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	23.87 million
Growth rate	CAGR of 8.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astellas Inc.; Johnson & Johnson; Sanofi S.A.; Dendreon Corporation; Bayer AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options